Valeo’s
Canadian Roots
Rooted in specialty pharma, Valeo is growing Canadian healthcare by licensing and acquiring Canadian rights to commercial stage, innovative, and proprietary drugs.
Listed on the TSX March 2022 and has secured
$60M+ Funding
Founded in 2003, Valeo Pharma originally focused on dermatology and Hospital specialty, until 2014 when it sold its entire product portfolio to Valeant ($27M).
Management and a growing base of employees (100+) is now refocused on large new therapeutic areas and commercializing drugs in Canada.
Since the sale, including financing of December 2021
$25M
Listed on the TSX March 2022 and has secured
$60M+ Funding
Since the sale, including financing of December 2021
$25M
Areas of Focus
Valeo’s company growth is coming by way of four therapeutic areas.
Within these four areas we now have 8 marketed brands and 4 additional products contributing to 100% growth in our 2021 revenues.
4
Therapeutic areas
8
Market Brands
4
Additional Products
This focused growth plan is already resulting in pivotal growth in 2021:
100%
Growth Estimated
Valeo’s Fully Integrated
Capabilities
Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization
